We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Withdraws Bextra; FDA Orders Labeling Changes for Entire NSAID Class
Pfizer Withdraws Bextra; FDA Orders Labeling Changes for Entire NSAID Class
April 8, 2005
The FDA announced April 7 a series of sweeping changes to the entire class of non-steroidal anti-inflammatory drugs (NSAIDs), including the withdrawal from the market of Pfizer’s Cox-2 selective inhibitor Bextra.